Late-stage results presented at a major cardiology meeting show Merck’s oral PCSK9 inhibitor produced LDL‑C reductions on par with existing injectable PCSK9 antibodies. In the CORALreef program Merck reported ~59% mean LDL lowering versus placebo at 24 weeks in key cohorts, data that analysts say could open primary‑care uptake and displace injectables if regulators approve the pill for high‑risk patients.